- No DFS benefit: Neoadjuvant chemotherapy did not significantly improve 3-year disease-free survival vs upfront surgery (83% vs 87%).
- Similar survival and safety: Overall survival, postoperative complications, adverse events, and quality of life were comparable between groups.
- Downstaging effect: Neoadjuvant therapy led to tumor downstaging, including a 3% complete pathologic response rate.
- Reduced adjuvant chemotherapy need: Fewer patients met criteria for postoperative chemotherapy (59% vs 73%).
- Exploratory subgroup signal: Outcomes varied by mismatch repair status, with numerically worse DFS in dMMR tumors treated with neoadjuvant therapy, though analyses were post hoc and underpowered.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
